Alnylam Pharmaceuticals, Inc. (LON:0HD2)
451.40
+7.94 (1.79%)
At close: Nov 28, 2025
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
1.07M GBP
Profits / Employee
14.53K GBP
Market Cap
45.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Alnylam Pharmaceuticals News
- 1 day ago - What's Going On With Alnylam Stock On Friday? - Benzinga
- 3 days ago - Virtus Silvant Mid-Cap Growth Fund Q3 2025 Performance Review - Seeking Alpha
- 8 days ago - Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
- 9 days ago - UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
- 9 days ago - High-Flying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double - Investor's Business Daily
- 10 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 18 days ago - Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALNY) | ALNY Stock News - GuruFocus
- 18 days ago - Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money - The Motley Fool